

Drug Class Review

Long-Acting Opioid Analgesics

Final Update 6 Evidence Tables

July 2011



The purpose of Drug Effectiveness Review Project reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs. Reports are not usage guidelines, nor should they be read as an endorsement of or recommendation for any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

Update 5: April 2008
Update 4: April 2006
Update 3: April 2005
Update 2: April 2004
Update 1: September 2003
Original Report: November 2002

Update 6 Authors
Susan Carson, MPH
Sujata Thakurta, MPA: HA
Allison Low, BA
Beth Smith, DO
Roger Chou, MD

Drug Effectiveness Review Project
Marian McDonagh, PharmD, Principal Investigator

Oregon Evidence-based Practice Center
Mark Helfand, MD, MPH, Director

Oregon Health & Science University

Copyright © 2011 by Oregon Health & Science University
Portland, Oregon 97239. All rights reserved.



Abbreviation	Term
SR	Sustained release
SSRIs	Selective serotonin reuptake inhibitors
tid	Three times daily
VAS	Visual analog scale
vs.	Compared with (versus)
WD	Withdrawal
WOMAC	Western Ontario and McMaster Universities Osteoarthritis Index
XR	Extended release
y	Year

Evidence Table 2. Update 6: Data abstraction of placebo-controlled trials

Author	Year	Country	Trial name (Quality rating- optional)	Harms	Total withdrawals; withdrawals due to adverse events	Funding	Comments
Munera, 2010		U.S.		<u>BTDS vs Placebo</u> Proportion of patients with any AE: 70% vs 53% Nausea: 27% vs 8%	<u>BTDS vs placebo</u> Overall withdrawal: 55% vs 47%	Purdue Pharma L.P.	
Fair				Headache: 22% vs 15% Dizziness: 20% vs 14% Somnolence: 15% vs 5% Pruritus at site: 13% vs 15% Vomiting: 11% vs 3% Constipation: 10% vs 2%	Due to AE: 24% vs 11%		

